• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Preclinical and clinical efficacy of trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity.曲妥珠单抗-德曲妥珠单抗治疗乳腺癌脑转移的临床前和临床疗效：对中枢神经系统活性的新见解。
Ann Transl Med. 2023 Oct 25;11(11):398. doi: 10.21037/atm-23-1603. Epub 2023 Oct 17.
2
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2 阳性乳腺癌伴中枢神经系统转移患者：DEBBRAH 试验。
Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144.
3
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.曲妥珠单抗-德鲁替康在乳腺癌脑转移中的临床前和临床疗效。
Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138.
4
Trastuzumab deruxtecan for HER2+ advanced breast cancer.曲妥珠单抗-德曲妥珠单抗用于治疗 HER2 阳性晚期乳腺癌。
Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26.
5
[A Case of Spinal Cord Metastasis from Breast Cancer Successfully Treated with Trastuzumab Deruxtecan].[一例成功接受曲妥珠单抗德鲁昔单抗治疗的乳腺癌脊髓转移病例]
Gan To Kagaku Ryoho. 2023 Jun;50(6):719-722.
6
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.曲妥珠单抗恩美曲妥珠单抗在 HER2 低表达三阴性乳腺癌中的应用：综述
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1061-1069. doi: 10.1080/14737140.2023.2257885. Epub 2023 Oct 26.
7
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.在 III 期 DESTINY-Breast03 研究中，接受曲妥珠单抗 deruxtecan 或曲妥珠单抗 emtansine 的 HER2 阳性转移性乳腺癌患者的患者报告结局和住院数据。
Ann Oncol. 2023 Jul;34(7):569-577. doi: 10.1016/j.annonc.2023.04.516. Epub 2023 May 12.
8
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.曲妥珠单抗-德鲁替康：一种用于治疗 HER2 阳性乳腺癌的研究药物。
Expert Opin Investig Drugs. 2020 Sep;29(9):901-910. doi: 10.1080/13543784.2020.1792443. Epub 2020 Jul 23.
9
Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.曲妥珠单抗-德鲁替康治疗既往治疗过的 HER2 低水平晚期乳腺癌的成本效果分析。
PLoS One. 2023 Aug 24;18(8):e0290507. doi: 10.1371/journal.pone.0290507. eCollection 2023.
10
Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis.曲妥珠单抗德瓦鲁单抗治疗HER2阳性乳腺癌伴垂体转移后视力显著恢复
Case Rep Oncol. 2023 Jul 7;16(1):491-496. doi: 10.1159/000531164. eCollection 2023 Jan-Dec.

本文引用的文献

1
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.曲妥珠单抗鞘内与其他给药途径用于 HER2 阳性乳腺癌脑膜转移患者的 HER2 靶向治疗的比较。
Breast. 2023 Jun;69:451-468. doi: 10.1016/j.breast.2023.04.008. Epub 2023 May 1.
2
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.接受曲妥珠单抗德曲妥珠单抗治疗的HER2阳性乳腺癌和软脑膜转移患者的持久反应。
NPJ Breast Cancer. 2023 Mar 30;9(1):19. doi: 10.1038/s41523-023-00519-0.
3
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.曲妥珠单抗-德鲁替康对比曲妥珠单抗-美坦新用于治疗 HER2 阳性转移性乳腺癌患者：来自随机、开放标签、III 期 DESTINY-Breast03 研究的更新结果。
Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7.
4
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.曲妥珠单抗-德鲁替康在乳腺癌脑转移中的临床前和临床疗效。
Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138.
5
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
6
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 低表达晚期乳腺癌。
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
7
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2 阳性乳腺癌伴中枢神经系统转移患者：DEBBRAH 试验。
Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144.
8
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.在 HER2CLIMB 试验中，曲妥珠单抗联合卡培他滨治疗既往治疗的 HER2 阳性乳腺癌伴脑转移的颅内疗效和生存。
J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29.
9
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
10
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.拉帕替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌伴未经治疗的脑转移患者（LANDSCAPE）：一项单组、Ⅱ期研究。
Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub 2012 Nov 2.

Preclinical and clinical efficacy of trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity.

作者信息

Batista Marta Vaz, Perez-Garcia José, Eiriz Inês, Gion Maria, Llombart Antonio, Braga Sofia, Cortés Javier

机构信息

Oncology Department, Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal.

Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, Ridgewood, NJ, USA.

出版信息

Ann Transl Med. 2023 Oct 25;11(11):398. doi: 10.21037/atm-23-1603. Epub 2023 Oct 17.

DOI:10.21037/atm-23-1603
PMID:37970592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10632579/
Abstract
摘要